Literature DB >> 9388109

In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation.

M Pan1, J Suárez de Lezo, A Medina, M Romero, E Hernández, J Segura, F Melian, F Wangüemert, M Landin, F Benítez, M Amat, F Velasco, A Torres.   

Abstract

Two hundred twenty-eight patients with successful coronary stent implantation were randomized either to protamine administration and femoral sheath removal (group I, n = 117) or no heparin neutralization and delayed sheath removal (group II, n = 111). The hospital stay after treatment was shorter in patients receiving protamine; therefore, protamine use for neutralizing circulating heparin may be safely administered immediately after stent implantation.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9388109     DOI： 10.1016/s0002-9149(97)00676-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


  18 in total

Review 1.  Antiplatelet therapy in interventional cardiology: II. Glycoprotein IIb/IIIa inhibitors.

Authors:  F H Jafary; C D Kimmelstiel
Journal:  J Thromb Thrombolysis       Date:  2000-02       Impact factor: 2.300

2.  Safety and efficacy outcomes of protamine administration for heparin reversal following cryoballoon-based pulmonary vein isolation.

Authors:  Kadri Murat Gurses; Duygu Kocyigit; Muhammed Ulvi Yalcin; Banu Evranos; Hikmet Yorgun; Mehmet Levent Sahiner; Ergun Baris Kaya; Mehmet Ali Oto; Necla Ozer; Kudret Aytemir
Journal:  J Interv Card Electrophysiol       Date:  2015-02-28       Impact factor: 1.900

3.  Three-dimensional culture using human plasma-medium gel with fragmin/protamine microparticles for proliferation of various human cells.

Authors:  Satoko Kishimoto; Masayuki Ishihara; Makoto Takikawa; Megumi Takikawa; Yuki Sumi; Shingo Nakamura; Masanori Fujita; Toshinori Sato; Tomoharu Kiyosawa
Journal:  Cytotechnology       Date:  2013-08-17       Impact factor: 2.058

4.  Delivery system for autologous growth factors fabricated with low-molecular-weight heparin and protamine to attenuate ischemic hind-limb loss in a mouse model.

Authors:  Shingo Nakamura; Megumi Takikawa; Masayuki Ishihara; Takefumi Nakayama; Satoko Kishimoto; Susumu Isoda; Yuichi Ozeki; Masahiro Sato; Tadaaki Maehara
Journal:  J Artif Organs       Date:  2012-08-14       Impact factor: 1.731

5.  Attenuation of limb loss in an experimentally induced hindlimb ischemic model by fibroblast growth factor-2/fragmin/protamine microparticles as a delivery system.

Authors:  Shingo Nakamura; Masayuki Ishihara; Megumi Takikawa; Satoko Kishimoto; Susumu Isoda; Masanori Fujita; Masahiro Sato; Tadaaki Maehara
Journal:  Tissue Eng Part A       Date:  2012-08-16       Impact factor: 3.845

6.  Safety and benefits of protamine administration to revert anticoagulation soon after coronary angioplasty. A meta-analysis.

Authors:  Giuseppe De Luca; Guido Parodi; David Antoniucci
Journal:  J Thromb Thrombolysis       Date:  2010-11       Impact factor: 2.300

7.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.

Authors:  Daniel M Witt; Robby Nieuwlaat; Nathan P Clark; Jack Ansell; Anne Holbrook; Jane Skov; Nadine Shehab; Juliet Mock; Tarra Myers; Francesco Dentali; Mark A Crowther; Arnav Agarwal; Meha Bhatt; Rasha Khatib; John J Riva; Yuan Zhang; Gordon Guyatt
Journal:  Blood Adv       Date:  2018-11-27

8.  Periprocedural outcomes of prophylactic protamine administration for reversal of heparin after cryoballoon ablation of atrial fibrillation.

Authors:  Giulio Conte; Carlo de Asmundis; Giannis Baltogiannis; Giacomo Di Giovanni; Giuseppe Ciconte; Juan Sieira; Yukio Saitoh; Kristel Wauters; Giacomo Mugnai; Justo Julià; Ghazala Irfan; Moises Levinstein; Hugo Enrique Cotino-Moreno; Gian-Battista Chierchia; Pedro Brugada
Journal:  J Interv Card Electrophysiol       Date:  2014-06-18       Impact factor: 1.900

9.  Preparation and characterization of low-molecular-weight heparin/protamine nanoparticles (LMW-H/P NPs) as FGF-2 carrier.

Authors:  Yasutaka Mori; Shingo Nakamura; Satoko Kishimoto; Mitsuyuki Kawakami; Satoshi Suzuki; Takemi Matsui; Masayuki Ishihara
Journal:  Int J Nanomedicine       Date:  2010-04-07

10.  Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy.

Authors:  Guido Parodi; Giuseppe De Luca; Guia Moschi; Benedetta Bellandi; Renato Valenti; Angela Migliorini; Nazario Carrabba; David Antoniucci
Journal:  J Thromb Thrombolysis       Date:  2010-11       Impact factor: 2.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.